{"url_path":"/sec/atnm/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-08","source_url":"https://www.sec.gov/Archives/edgar/data/1388320/0001213900-26-053980-index.html","accession_number":"0001213900-26-053980","cik":"0001388320","ticker":"ATNM","issuer_name":"Actinium Pharmaceuticals, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1388320/0001213900-26-053980-index.html","primary_entity_key":"0001388320","primary_entity_name":"Actinium Pharmaceuticals, Inc."},"word_count":428,"has_tables":true,"body_markdown":"**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-Q**\n\n \n\n(Mark One)\n\n☒** QUARTERLY REPORT PURSUANT TO SECTION\n13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the quarterly period ended **March 31, 2026**\n\n \n\nor\n\n \n\n☐** TRANSITION REPORT PURSUANT TO SECTION\n13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the transition period from __________ to __________\n\n \n\nCommission File Number: **001-36374**\n\n \n\n**ACTINIUM PHARMACEUTICALS, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**   **74-2963609**\n\n(State or Other Jurisdiction of\n\nIncorporation or Organization)   (I.R.S. Employer*\n\nIdentification No.)\n\n     \n\n**100 Park Ave., 23rd Floor**\n\n**New York, NY**\n  **10017**\n\n(Address of Principal Executive Offices)   (Zip Code)\n\n \n\n**(646) 677-3870**\n\n(Registrant’s Telephone Number, Including\nArea Code)\n\n \n\n**Securities registered pursuant to Section 12(b)\nof the Act:**\n\n \n\n**Title of each class**   **Trading Symbol**    **Name of exchange on which registered**\n\n**Common stock, par value $0.001**   **ATNM**   **NYSE American**\n\n  \n\nIndicate by check mark whether\nthe registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the\npreceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such\nfiling requirements for the past 90 days. ☒ Yes  No ☐\n\n \n\nIndicate by check mark whether\nthe registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T\n(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit\nsuch files). ☒ Yes No ☐\n\n \n\nIndicate by check mark whether\nthe registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging\ngrowth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting\ncompany,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer ☐ Accelerated filer ☐\n\nNon-accelerated filer ☒  Smaller reporting company ☒\n\n    Emerging growth company ☐ \n\n \n\nIf an emerging growth company,\nindicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial\naccounting standards, provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether\nthe registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No\n\n \n\nIndicate the number of shares\noutstanding of each of the issuer’s classes of common stock, as of May 7, 2026: 31,374,991\n\n \n\n \n\n \n\n \n\n**Actinium Pharmaceuticals, Inc.**\n\n \n\n**Table of Contents** \n\n**INDEX**\n\n \n\n**PART I – FINANCIAL INFORMATION**"}